The Medical Advisor

Mebendazole is an established antiparasitic medicine that has attracted attention as a potential repurposed cancer drug. Laboratory studies and animal models have reported anticancer activity, while a small number of published human cases and early clinical trials have generated interest. Important: Mebendazole is not an established cancer treatment and should not be substituted for evidence-based oncology care. Some human studies are encouraging, while others have produced limited or inconclusive results. The strongest interpretation of the evidence is that mebendazole remains an investigational repurposing candidate , not a proven cancer cure. This 2026 update reviews the evidence behind commonly cited “ mebendazole cancer success stories ,” including published human case reports, randomized and early-phase clinical studies, preclinical research, and the limitations of anecdotal reports. Editorial update: September 2026 ...

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: October 2026 Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories (130 cases) Brain Cancer (including Glioblastoma) (135 cases) Bladder Cancer Success Stories  (including kidney cancer) (38 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (87 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (13 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer )  Head and Neck Cancer (17 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) Liver and Bile Duct Cancer  (Hepato-biliary system) (9 cases) Lung Cancer (63 cases) Leukemia (15 cases) Lymphoma (30 cases) Melanoma (refer to...